News and Media

Product Launch Announcement: Iverclear 20 (Ivermectin 20mg) Tablet We are proud to introduce Iverclear 20 is an oral antiparasitic medication containing Ivermectin 20mg, widely used for the treatment of various parasitic infections. It is known for its broad-spectrum activity, well-established safety profile, and effectiveness in both individual and mass treatment programs. 🔍 Product Overview Generic Name:…

Product Launch Announcement: Dasib 50 (Dasatinib 50mg) Tablet We are proud to introduce Dasib 50 is an oral targeted anti-cancer therapy containing Dasatinib 50mg, developed for the treatment of specific hematological malignancies. As a potent tyrosine kinase inhibitor, Dasib 50 offers effective disease control in patients with chronic myeloid leukemia and related conditions, supporting improved clinical…

Product Launch Announcement: Axilyta 5 (Axitinib 5mg) Tablet We are proud to introduce Axilyta 5 is a targeted oral anti-cancer therapy containing Axitinib 5mg, designed for the effective management of advanced renal cell carcinoma. As a potent and selective tyrosine kinase inhibitor, Axilyta 5 helps inhibit tumor angiogenesis, slowing disease progression and improving clinical outcomes. 🔍…

Product Launch Announcement: Abiramale 500 (Abiraterone Acetate 500mg) Tablet We are proud to introduce Abiramale 500 is an oral hormonal anti-cancer therapy containing Abiraterone Acetate 500mg, indicated for the management of advanced prostate cancer. By effectively suppressing androgen production, Abiramale 500 helps slow disease progression and supports improved survival outcomes in patients with metastatic disease. 🔍…

Product Launch Announcement: Sorafemax 200 (Sorafenib 200mg) Tablet We are proud to introduce Sorafemax 200 is a prescription oral anticancer medication containing Sorafenib 200mg, a well-established multikinase inhibitor used in the management of specific advanced cancers. Designed to inhibit tumor cell proliferation and angiogenesis, Sorafemax 200 (Sorafenib 200mg) plays a critical role in targeted cancer therapy….

🚀Product Launch Announcement: Enzamale 40 (Enzalutamide 40mg) Capsules We are proud to introduce Enzamale 40 (Enzalutamide 40 mg) capsule is an advanced androgen-receptor inhibitor formulated to support the treatment of metastatic and non-metastatic castration-resistant prostate cancer (mCRPC & nmCRPC). Designed with high-purity API and optimized bioavailability, Enzamale delivers consistent therapeutic performance by blocking key androgen-receptor signaling…

🚀Product Launch: Abiramale 250 We are proud to introduce Abiramale 250 contains Abiraterone Acetate 250 mg, an advanced androgen-biosynthesis inhibitor designed to improve outcomes in metastatic castration-resistant prostate cancer (mCRPC).By selectively inhibiting the CYP17 enzyme, Abiramale 250 reduces androgen production from the testes, adrenal glands, and tumor tissue—helping slow disease progression and enhance patient survival. Designed…

🚀 Product Launch Content: Molnuheal 200 We are proud to introduce Molnuheal 200, an oral antiviral formulation containing Molnupiravir 200 mg, designed to address the urgent need for early outpatient treatment of mild to moderate COVID-19 infection in adults at high risk of disease progression. Molnuheal 200 represents a critical step in outpatient COVID-19 management—helping…

🚀 Product Launch Content: Starquin 200 We are pleased to introduce Starquin 200, a clinically trusted formulation of Hydroxychloroquine Sulphate 200 mg, developed to meet the evolving needs in the management of rheumatoid arthritis and systemic lupus erythematosus (SLE). As a cornerstone in autoimmune disease therapy, Starquin 200 delivers consistent efficacy, excellent tolerability, and long-term…

🚀 Product Launch Content: Parziworm 600 We are proud to introduce Parziworm 600, an advanced, high-strength antiparasitic formulation featuring Praziquantel 600 mg, specially designed for the treatment of tapeworm infections, Schistosomiasis, and liver fluke infestations. Backed by robust clinical evidence and global therapeutic relevance, Parziworm 600 stands as a trusted choice for healthcare professionals seeking…